Skip to main content
. 2016 Mar 10;7(16):22605–22622. doi: 10.18632/oncotarget.8027

Figure 8. Specific depletion of Ly6G highlights neutrophils as a restraining factor for Symbioflor-2 mediated tumor therapy.

Figure 8

RenCa tumor bearing mice received a daily injection i.p. of 25 μg anti-Gr-1 mAb (RB6-8C5) or anti-Ly6G mAb (1A8). A. Tumor development in mice subjected to infection with SL7207 or Symbioflor-2 alone or in combination with anti-Gr-1 mAb (α-Gr-1) or anti-Ly6G mAb (α-Ly6G). B. Comparable endpoint tumor volume between SL7207 infection and combination treatments Symbioflor-2/ α-Ly6G and Symbioflor-2/ α-Gr-1. N=5. Mean ± SEM.